https://www.aronresearchfoundation.com/en/blogs/pubblicazioni-scientifiche/efficacia-di-enfortumab-vedotin-nel-trattamento-di-pazienti-con-carcinoma-uroteliale-e-metastasi-ossee 2026-03-10T19:13:09+01:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Bone_metastases_ARON-2EV.jpg?v=1773166389 https://www.aronresearchfoundation.com/en/blogs/pubblicazioni-scientifiche/pembrolizumab-post-chirurgia-nel-tumore-del-rene-i-nuovi-dati-real-world-dal-network-aron 2026-03-10T19:08:57+01:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/rene.jpg?v=1773166137 https://www.aronresearchfoundation.com/en/blogs/news/una-nuova-frontiera-nell-uso-dell-immunoterapia-e-delle-terapie-a-bersaglio-al-posto-della-chemioterapia-nelle-fasi-perioperatorie-in-pazienti-con-neoplasie-vescicali 2026-03-10T19:15:09+01:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/necchi.jpg?v=1773166509 https://www.aronresearchfoundation.com/en/blogs/news/microplastiche-in-pazienti-con-tumori-prostatici 2026-03-10T19:17:51+01:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/W5xuo2_QTmw7V7QNuwdTA_bd21574c-a937-4bf0-a6e4-a8dccf83326e.webp?v=1773166671 https://www.aronresearchfoundation.com/en/blogs/news/congresso-6-7-maggio-promosso-dall-aron-research-foundation-ets 2026-03-10T19:01:10+01:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/6-7_Maggio.jpg?v=1773165670 https://www.aronresearchfoundation.com/en/blogs/news/le-nostre-eccellenze-il-dottor-alessandro-rizzo-vincitore-del-prestigioso-esmo-merit-award-2026 2026-10-06T09:54:13+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_93z99m93z99m93z9_f4673f93-c531-423f-be6a-2558d90ae543.png?v=1791273253 https://www.aronresearchfoundation.com/en/blogs/aron-1/caratteristiche-clinico-patologiche-che-influenzano-il-ruolo-prognostico-dellindice-di-massa-corporea-nei-pazienti-con-carcinoma-a-cellule-renali-avanzato-trattati-con-combinazioni-di-immuno-oncologia-aron-1 2026-10-06T15:10:50+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_8i53tc8i53tc8i53_d990a395-2051-430e-84f6-027c088818d1.jpg?v=1791292250 https://www.aronresearchfoundation.com/en/blogs/aron-1/risultati-globali-nella-pratica-clinica-reale-di-pazienti-sottoposti-a-combinazioni-di-immuno-oncologia-per-carcinoma-a-cellule-renali-avanzato-lo-studio-aron-1 2026-10-06T15:11:30+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_cfzx76cfzx76cfzx_d3e17f1a-fba9-462c-a24f-05ba2796c7fc.jpg?v=1791292290 https://www.aronresearchfoundation.com/en/blogs/aron-1/differenze-geografiche-nella-gestione-del-carcinoma-a-cellule-renali-metastatico-de-novo-nellera-delle-immunocombinazioni 2026-10-06T15:12:47+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_a0yhzla0yhzla0yh_024503fa-fbd3-488e-acd1-feb9e0e1a214.jpg?v=1791292367 https://www.aronresearchfoundation.com/en/blogs/aron-2/aron-2-efficacia-nel-mondo-reale-del-pembrolizumab-come-terapia-di-prima-linea-per-pazienti-con-carcinoma-uroteliale-avanzato-non-idonei-al-cisplatino-lo-studio-aron-2 2026-10-09T11:23:03+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_9enpvx9enpvx9enp_ae22332b-3261-4690-a2e3-52c701fe4288.jpg?v=1791293942 https://www.aronresearchfoundation.com/en/blogs/aron-1/differenze-geografiche-nella-gestione-del-carcinoma-a-cellule-renali-metastatico-de-novo-nellera-delle-immunocombinazioni-1 2026-10-06T15:10:37+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_cigcx3cigcx3cigc_3aa0a2c0-38ab-4dfb-a829-b2008fd0fdbd.jpg?v=1791292237 https://www.aronresearchfoundation.com/en/blogs/aron-1/aron-1-indice-di-infiammazione-immunitaria-sistemica-nei-pazienti-trattati-con-immunocombinazioni-di-prima-linea-per-carcinoma-a-cellule-renali-metastatico-spunti-dallo-studio-aron-1 2026-10-06T15:12:56+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_qm1m7zqm1m7zqm1m_c3b186b6-b121-49de-9c3b-000c973e478b.jpg?v=1791292376 https://www.aronresearchfoundation.com/en/blogs/aron-1/validazione-esterna-di-un-punteggio-prognostico-ematico-basato-sui-globuli-rossi-in-pazienti-con-carcinoma-a-cellule-renali-metastatico-trattati-con-combinazioni-di-immunoterapia-di-prima-linea 2026-10-07T10:14:18+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_c4fw46c4fw46c4fw.jpg?v=1791360845 https://www.aronresearchfoundation.com/en/blogs/aron-1/sesso-e-risultati-di-sopravvivenza-nei-pazienti-con-carcinoma-a-cellule-renali-trattati-con-terapie-di-prima-linea-a-base-di-immunoterapie 2026-10-07T10:31:54+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_jpw1xljpw1xljpw1.jpg?v=1791361914 https://www.aronresearchfoundation.com/en/blogs/aron-1/impatto-reale-della-nefrectomia-citoriduttiva-iniziale-nel-carcinoma-renale-non-a-cellule-chiare-metastatico-trattato-con-combinazioni-di-immunoterapia-di-prima-linea-o-inibitori-della-tirosin-chinasi-una-sottoanalisi-dello-studio-retrospettivo-aron-1 2026-10-07T11:20:46+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_drob5jdrob5jdrob.jpg?v=1791362095 https://www.aronresearchfoundation.com/en/blogs/aron-1/carcinoma-papillare-a-cellule-renali-esiti-per-i-pazienti-trattati-con-combinazioni-immunologiche-di-prima-linea-o-inibitori-della-tirosin-chinasi-nello-studio-aron-1 2026-10-07T12:18:58+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_ez6twgez6twgez6t.jpg?v=1791368313 https://www.aronresearchfoundation.com/en/blogs/aron-1/resistenza-primaria-nel-mondo-reale-alle-combinazioni-immunologiche-di-prima-linea-in-pazienti-con-carcinoma-a-cellule-renali-avanzato-aron-1 2026-10-07T12:21:52+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_e1ycpze1ycpze1yc.jpg?v=1791368512 https://www.aronresearchfoundation.com/en/blogs/aron-1/caratteristiche-cliniche-e-risposta-alle-immunocombinazioni-in-pazienti-con-carcinoma-a-cellule-renali-e-de-differenziazione-sarcomatoide-studio-aron-1 2026-10-07T12:33:36+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_2pr7m72pr7m72pr7.jpg?v=1791369168 https://www.aronresearchfoundation.com/en/blogs/aron-1/combinazioni-immunologiche-di-prima-linea-o-sunitinib-nel-carcinoma-a-cellule-renali-metastatico-a-basso-rischio-un-confronto-retrospettivo-nella-pratica-clinica-reale-dallo-studio-aron-1 2026-10-07T12:42:23+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Immagine6.jpg?v=1791369743 https://www.aronresearchfoundation.com/en/blogs/aron-1/pembrolizumab-axitinib-versus-nivolumab-cabozantinib-come-terapia-di-prima-linea-in-pazienti-con-carcinoma-a-cellule-renali-metastatico-uno-studio-retrospettivo-di-confronto-nella-pratica-clinica-reale-aron-1 2026-10-09T09:37:21+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_e5gecue5gecue5ge.jpg?v=1791531438 https://www.aronresearchfoundation.com/en/blogs/aron-1/nivolumab-piu-cabozantinib-nel-carcinoma-a-cellule-renali-metastatico-evidenze-dal-mondo-reale-dello-studio-internazionale-aron-1 2026-10-09T09:38:50+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_pibg0gpibg0gpibg.jpg?v=1791531530 https://www.aronresearchfoundation.com/en/blogs/aron-1/spressione-dellmrna-eterogeneita-tumorale-e-risposta-alla-terapia-in-pazienti-con-carcinoma-a-cellule-renali-avanzato-trattati-con-combinazioni-immunologiche-aron-1%CE%B1 2026-10-09T09:40:30+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_qx05rnqx05rnqx05.jpg?v=1791531630 https://www.aronresearchfoundation.com/en/blogs/aron-1/combinazioni-immunologiche-in-pazienti-a-rischio-intermedio-alto-con-carcinoma-renale-non-a-cellule-chiare-risultati-dello-studio-aron-1 2026-10-09T09:41:38+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_iu7w04iu7w04iu7w.jpg?v=1791531692 https://www.aronresearchfoundation.com/en/blogs/aron-1/differenziazione-sarcomatoide-nel-carcinoma-a-cellule-renali-eterogeneita-clinica-e-patologica-e-risultati-con-gli-inibitori-dei-checkpoint-immunitari-dati-dello-studio-aron-1 2026-10-09T09:45:12+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_q2p17hq2p17hq2p1.jpg?v=1791531912 https://www.aronresearchfoundation.com/en/blogs/aron-1/ruolo-del-rapporto-hb-rdw-nei-pazienti-con-carcinoma-a-cellule-renali-metastatico-trattati-con-immunoterapie-di-prima-linea 2026-10-09T09:35:18+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_r6f0e0r6f0e0r6f0.jpg?v=1791530547 https://www.aronresearchfoundation.com/en/blogs/aron-1/pembrolizumab-piu-lenvatinib-in-pazienti-con-carcinoma-a-cellule-renali-metastatico-evidenze-dal-mondo-reale-dello-studio-internazionale-aron-1 2026-10-09T09:35:27+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_3r61d23r61d23r61.jpg?v=1791531252 https://www.aronresearchfoundation.com/en/blogs/aron-1/evidenze-dal-mondo-reale-sullefficacia-del-pembrolizumab-adiuvante-nel-carcinoma-a-cellule-renali-risultati-dello-studio-multicentrico-aron-1-condotto-in-condizioni-di-pratica-clinica-reale 2026-10-09T10:02:46+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_5ubbn35ubbn35ubb.jpg?v=1791532848 https://www.aronresearchfoundation.com/en/blogs/aron-1/interruzione-dellimmunoterapia-correlata-alla-tossicita-ed-esito-nei-pazienti-con-carcinoma-a-cellule-renali-avanzato-trattati-con-combinazioni-immunologiche-studio-aron-1 2026-10-09T10:16:54+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_3qruc83qruc83qru.jpg?v=1791533794 https://www.aronresearchfoundation.com/en/blogs/aron-2/uso-concomitante-di-inibitori-della-pompa-protonica-statine-o-metformina-in-pazienti-trattati-con-pembrolizumab-per-carcinoma-uroteliale-metastatico-dati-dello-studio-retrospettivo-aron-2 2026-10-09T11:26:14+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_ocfatzocfatzocfa.jpg?v=1791537974 https://www.aronresearchfoundation.com/en/blogs/aron-2/gli-agenti-che-agiscono-sul-tessuto-osseo-ma-non-la-radioterapia-migliorano-la-sopravvivenza-nei-pazienti-con-metastasi-ossee-da-carcinoma-uroteliale-avanzato-trattati-con-pembrolizumab-risultati-dello-studio-aron-2 2026-10-09T11:28:37+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_gien0cgien0cgien_1_f378572e-87f4-4613-b351-30e81b2aa1c3.jpg?v=1791538114 https://www.aronresearchfoundation.com/en/blogs/aron-2/esperienze-globali-di-pratica-clinica-reale-con-pembrolizumab-nel-carcinoma-uroteliale-avanzato-dopo-chemioterapia-a-base-di-platino-lo-studio-aron-2 2026-10-09T11:32:30+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_j5tkeyj5tkeyj5tk.jpg?v=1791538346 https://www.aronresearchfoundation.com/en/blogs/aron-2/radiotherapy-plus-pembrolizumab-for-advanced-urothelial-carcinoma-results-from-the-aron-2-real-world-study 2026-10-09T11:35:16+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_da0bhfda0bhfda0b.jpg?v=1791538511 https://www.aronresearchfoundation.com/en/blogs/aron-3/apalutamide-nel-carcinoma-prostatico-metastatico-sensibile-alla-castrazione-risultati-dello-studio-multicentrico-aron-3-condotto-nella-pratica-clinica-reale 2026-10-09T12:20:51+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_tjsrlrtjsrlrtjsr.jpg?v=1791541251 https://www.aronresearchfoundation.com/en/blogs/supplementary/apalutamide-nel-carcinoma-prostatico-metastatico-sensibile-alla-castrazione-risultati-dello-studio-multicentrico-aron-3-condotto-nella-pratica-clinica-reale 2026-10-09T12:24:10+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_29a1x529a1x529a1.jpg?v=1791541450 https://www.aronresearchfoundation.com/en/blogs/aron-2/pembrolizumab-in-pazienti-con-carcinoma-uroteliale-avanzato-con-performance-status-ecog-2-uno-studio-di-pratica-clinica-reale-del-progetto-aron-2 2026-10-09T13:31:20+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_uqd22tuqd22tuqd2.jpg?v=1791545480 https://www.aronresearchfoundation.com/en/blogs/aron-2/pembrolizumab-in-pazienti-con-carcinoma-uroteliale-avanzato-delle-vie-urinarie-superiori-uno-studio-in-condizioni-di-pratica-clinica-reale-del-progetto-aron-2 2026-10-09T13:28:15+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_301lb7301lb7301l.jpg?v=1791545295 https://www.aronresearchfoundation.com/en/blogs/aron-2/enfortumab-vedotin-dopo-chemioterapia-al-platino-e-terapia-di-mantenimento-con-avelumab-in-pazienti-con-carcinoma-uroteliale-metastatico-dati-retrospettivi-dello-studio-aron-2-ev 2026-10-09T15:30:47+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_8566mt8566mt8566.jpg?v=1791552619 https://www.aronresearchfoundation.com/en/blogs/aron-2/impatto-reale-di-enfortumab-vedotin-o-della-chemioterapia-nel-trattamento-sequenziale-del-carcinoma-uroteliale-avanzato-lesperienza-retrospettiva-dello-studio-aron-2 2026-10-09T15:33:29+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_bkhr6zbkhr6zbkhr.jpg?v=1791552791 https://www.aronresearchfoundation.com/en/blogs/aron-2/farmaci-concomitanti-in-pazienti-con-carcinoma-uroteliale-metastatico-trattati-con-enfortumab-vedotin-dati-di-pratica-clinica-reale-dallo-studio-aron-2-ev 2026-10-09T15:37:13+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_4sp4ym4sp4ym4sp4.jpg?v=1791553033 https://www.aronresearchfoundation.com/en/blogs/aron-2/il-sesso-come-fattore-modificatore-della-sopravvivenza-nei-pazienti-con-carcinoma-uroteliale-avanzato-trattati-con-pembrolizumab 2026-10-09T15:41:35+02:00 weekly https://cdn.shopify.com/s/files/1/0899/1201/7229/articles/Gemini_Generated_Image_xmgz7jxmgz7jxmgz.jpg?v=1791553295